The correct dosage and method of taking nintedanib

Nintedanib (Nintedanib) is an oral small molecule tyrosine kinase inhibitor, mainly used to treat idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and other types of chronic progressive interstitial lung diseases. Its mechanism of action mainly slows down the process of pulmonary fibrosis by inhibiting various tyrosine kinases (such as VEGFR, FGFR, PDGFR). In order to achieve the best therapeutic effect, patients must strictly follow the standardized medication method when taking it.

Generally, the recommended dose of nintedanib is 150 mg twice daily with doses approximately 12 hours apart. To reduce gastrointestinal adverse reactions, it is recommended to take it with or after meals. Nintedanib is in the form of a soft capsule, which needs to be swallowed whole and cannot be chewed or crushed to prevent damage to the coating structure of the drug, affect the efficacy of the drug, or cause irritant reactions.

If you miss a dose while taking the medicine, you should take it as soon as possible. If it is close to the time of the next dose, you should skip the missed dose and never double the dose. In addition, you must pay attention to liver function monitoring while taking the drug, especially before and within the first 3 months. It is recommended to test liver enzymes monthly, and then every 3 months to prevent drug-related liver damage. If ALT or AST is detected to be elevated more than 3 times the upper limit of normal, or combined with elevated bilirubin, the dose needs to be suspended or adjusted.

For patients who experience adverse reactions such as severe diarrhea, nausea, or vomiting, dose adjustment should be considered, usually reducing 150 mg twice daily to 100 mg twice daily. Once symptoms subside, try to resume standard dosage. Nintedanib is not recommended for use in patients with moderately or severely impaired hepatic function. During treatment, concomitant use with other strong enzyme inhibitors or inducers should be avoided to avoid affecting drug metabolism.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib